Company Overview and News

 
ULSGF / UBS AG PPS - AAPL EL NVDA UPS TACYN WMA (US90281B1558 US90281B1632 US90281B1715 US90281B1897) (Prospectus)

6h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. We may not sell these Notes until the pricing supplement, the TACYN product supplement and the accompanying prospectus (collectively, the “Offering Documents”) are delivered in final form. The Offering Documents are not an offer to sell these Notes and we are not soliciting offers to buy these Notes in any state where the offer or sale is not permitted.
ULSGF

 
ULSGF / UBS AG PS - SPX BARRIER ABSOLUTE RETURN MARKET LINKED NOTES WMA (US90270KTR04) (Prospectus)

22h sec.gov
PRICING SUPPLEMENT Dated September 14, 2018 Filed Pursuant to Rule
ULSGF

 
ULSGF / UBS AG TC4724770I_0FWP.HTM (Prospectus)

23h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement,the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Secur
ULSGF

 
ULSGF / UBS AG TC4724770F_1FWP.HTM (Prospectus)

23h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-204908
ULSGF

 
ULSGF / UBS AG TC4724771I_0FWP.HTM (Prospectus)

23h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement,the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Secur
ULSGF

 
ULSGF / UBS AG TC4724771F_1FWP.HTM (Prospectus)

23h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-204908
ULSGF

 
ULSGF / UBS AG TC4724772I_0FWP.HTM (Prospectus)

23h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement,the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Secur
ULSGF

 
ULSGF / UBS AG TC4724772F_1FWP.HTM (Prospectus)

23h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-204908
ULSGF

 
ULSGF / UBS AG TC4724773I_0FWP.HTM (Prospectus)

23h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Notes until the Final Terms Supplement, the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Notes, and we are not soliciting offers to buy these Notes, in any
ULSGF

 
ULSGF / UBS AG TC4724773F_1FWP.HTM (Prospectus)

23h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-204908
ULSGF

 
ULSGF / UBS AG TC4724774I_0FWP.HTM (Prospectus)

23h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement,the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Secur
ULSGF

 
ULSGF / UBS AG TC4724774F_1FWP.HTM (Prospectus)

23h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-204908
ULSGF

 
ULSGF / UBS AG TC4724775I_0FWP.HTM (Prospectus)

23h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement,the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Secur
ULSGF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 0H8923133